菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletter: October 2023

Partner News

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

 

Read More

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

 

Read More

WuXi Biologics Announced Global Strategic Partnership with Pharmadule Morimatsu at its Singapore CRDMO Center Project

 

Read More

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

 

Read More

WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics

 

Read More


Company News

WuXi Biologics Announces Proposed Spin-off and Separate Listing of WuXi XDC on the Hong Kong Stock Exchange

 

Read More

WuXi Biologics to Increase Manufacturing Capacity in Germany

 

Read More


Financials

WuXi Biologics Reports Solid 2023 Interim Results

 

Read More


Regulatory Updates

First half calendar year updates in the ever-changing regulatory environment for biological therapeutics and vaccines.

 

Read More


Sustainability

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

 

Read More